| Oct 17 |
Kezar Life Sciences Rejects Concentra Biosciences Takeover Bid, Adopts Rights Plan
|
| Oct 17 |
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
|
| Oct 17 |
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
|
| Oct 15 |
What Makes Kezar Life Sciences (KZR) a New Buy Stock
|
| Oct 10 |
Kezar receives acquisition proposal from Concentra for $1.10 per share
|
| Oct 10 |
Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal
|
| Oct 9 |
Why Saratoga Investment Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
|
| Oct 8 |
TANG CAPITAL MANAGEMENT LLC Acquires New Stake in Kezar Life Sciences Inc
|
| Oct 7 |
FDA Put Brakes On Penny Stock Kezar Life Sciences' Mid-Stage Study For Lead Development Candidate After Patient Deaths
|
| Oct 7 |
FDA places hold on Kezar Life Sciences’ trial for lupus nephritis treatment
|
